Search
| (ENZN) NASDAQ | |||
| Last Trade | 9.30 | ||
| Change(%) | ![]() | +0.01 | |
| Volume | 829038 | ||
| 4:44 PM - Feb 24, 2010 | |||
News
Enzon to Present at NewsMakers in the Biotech Industry Conference
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
Enzon to Present at BMO Focus on Healthcare Conference
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director

Enzon Treats Patients with Survivin Antagonist
-- Enzon's compound advances into the clinic for patients with solid tumors and lymphomas--
Enzon to Present at 29th Annual Cowen and Company Conference
Enzon Reports Solid Second Quarter 2008 Results
-- Product revenues increase 17% --
Enzon Pharmaceuticals Commences Tender Offer For a Portion of its Debt

Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director
Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO
-- First specific HIF-1a inhibitor is well tolerated with early signs of clinical benefit--
Enzon's Board of Directors Reaffirms Support of its Chairman and CEO
Enzon Announces IND Acceptance for its Survivin Antagonist
-- Phase I study to open for patients with solid tumors--
